Literature DB >> 33585190

Proteomic Alterations in Multiple Myeloma: A Comprehensive Study Using Bone Marrow Interstitial Fluid and Serum Samples.

Venkatesh Chanukuppa1,2, Ravindra Taware1, Khushman Taunk1, Tathagat Chatterjee3, Sanjeevan Sharma4, Venkatesan Somasundaram4, Faraz Rashid5, Dipankar Malakar5, Manas K Santra6, Srikanth Rapole1.   

Abstract

Multiple myeloma (MM) is a plasma cell-associated cancer and exists as the second most common hematological malignancy worldwide. Although researchers have been working on MM, a comprehensive quantitative Bone Marrow Interstitial Fluid (BMIF) and serum proteomic analysis from the same patients' samples is not yet reported. The present study involves the investigation of alterations in the BMIF and serum proteome of MM patients compared to controls using multipronged quantitative proteomic approaches viz., 2D-DIGE, iTRAQ, and SWATH-MS. A total of 279 non-redundant statistically significant differentially abundant proteins were identified by the combination of three proteomic approaches in MM BMIF, while in the case of serum 116 such differentially abundant proteins were identified. The biological context of these dysregulated proteins was deciphered using various bioinformatic tools. Verification experiments were performed in a fresh independent cohort of samples using immunoblotting and mass spectrometry based SRM assays. Thorough data evaluation led to the identification of a panel of five proteins viz., haptoglobin, kininogen 1, transferrin, and apolipoprotein A1 along with albumin that was validated using ELISA in a larger cohort of serum samples. This panel of proteins could serve as a useful tool in the diagnosis and understanding of the pathophysiology of MM in the future.
Copyright © 2021 Chanukuppa, Taware, Taunk, Chatterjee, Sharma, Somasundaram, Rashid, Malakar, Santra and Rapole.

Entities:  

Keywords:  2D-DIGE; SWATH-MS; bone marrow interstitial fluid; iTRAQ; multiple myeloma; multipronged quantitative proteomics; serum biomarkers

Year:  2021        PMID: 33585190      PMCID: PMC7879980          DOI: 10.3389/fonc.2020.566804

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  84 in total

Review 1.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

2.  Hypoalbuminemia in patients with multiple myeloma.

Authors:  Y H Chen; M C Magalhaes
Journal:  Arch Intern Med       Date:  1990-03

3.  Urinary proteome alterations in HER2 enriched breast cancer revealed by multipronged quantitative proteomics.

Authors:  Akshada Gajbhiye; Raju Dabhi; Khushman Taunk; Garikapati Vannuruswamy; Sourav RoyChoudhury; Ragini Adhav; Shubhendu Seal; Anupama Mane; Santhakumari Bayatigeri; Manas K Santra; Koel Chaudhury; Srikanth Rapole
Journal:  Proteomics       Date:  2016-08-05       Impact factor: 3.984

4.  Evaluation of serum amyloid A as a biomarker for gastric cancer.

Authors:  De-Chuan Chan; Cheng-Jueng Chen; Heng-Cheng Chu; Wei-Kuo Chang; Jyh-Cherng Yu; Yu-Ju Chen; Li-Li Wen; Su-Ching Huang; Chih-Hung Ku; Yao-Chi Liu; Jenn-Han Chen
Journal:  Ann Surg Oncol       Date:  2006-10-25       Impact factor: 5.344

5.  High-throughput screening of tumor metastatic-related differential glycoprotein in hepatocellular carcinoma by iTRAQ combines lectin-related techniques.

Authors:  Xue Qin; Qiaopei Chen; Chun Sun; Cun Wang; Qiliu Peng; Li Xie; Yinkun Liu; Shan Li
Journal:  Med Oncol       Date:  2013-01-06       Impact factor: 3.064

6.  Differential expression of serum proteins in multiple myeloma.

Authors:  Tian-Ze Ma; Zhe Piao; Sheng-Yu Jin; Yong-Geun Kwak
Journal:  Exp Ther Med       Date:  2018-11-23       Impact factor: 2.447

7.  Bradykinin promotes the chemotactic invasion of primary brain tumors.

Authors:  Vedrana Montana; Harald Sontheimer
Journal:  J Neurosci       Date:  2011-03-30       Impact factor: 6.167

8.  Oxidative stress in lung cancer patients is associated with altered serum markers of lipid metabolism.

Authors:  Katarzyna Zabłocka-Słowińska; Sylwia Płaczkowska; Katarzyna Skórska; Anna Prescha; Konrad Pawełczyk; Irena Porębska; Monika Kosacka; Halina Grajeta
Journal:  PLoS One       Date:  2019-04-11       Impact factor: 3.240

9.  Biomarkers for the differentiation of anemia and their clinical usefulness.

Authors:  Christine A Northrop-Clewes; David I Thurnham
Journal:  J Blood Med       Date:  2013-03-20

10.  2016 update of the PRIDE database and its related tools.

Authors:  Juan Antonio Vizcaíno; Attila Csordas; Noemi del-Toro; José A Dianes; Johannes Griss; Ilias Lavidas; Gerhard Mayer; Yasset Perez-Riverol; Florian Reisinger; Tobias Ternent; Qing-Wei Xu; Rui Wang; Henning Hermjakob
Journal:  Nucleic Acids Res       Date:  2015-11-02       Impact factor: 16.971

View more
  4 in total

1.  Patient-Derived Extracellular Vesicles Proteins as New Biomarkers in Multiple Myeloma - A Real-World Study.

Authors:  Bruna Velosa Ferreira; Emilie Arnault Carneiro; Carolina Pestana; Filipa Barahona; Joana Caetano; Raquel Lopes; Paulo Lúcio; Manuel Neves; Hans Christian Beck; Ana Sofia Carvalho; Rune Matthiesen; Bruno Costa-Silva; Cristina João
Journal:  Front Oncol       Date:  2022-06-21       Impact factor: 5.738

2.  Nontargeted and targeted metabolomics approaches reveal the key amino acid alterations involved in multiple myeloma.

Authors:  Lingling Yue; Pengyun Zeng; Yanhong Li; Ye Chai; Chongyang Wu; Bingren Gao
Journal:  PeerJ       Date:  2022-02-09       Impact factor: 2.984

3.  iTRAQ-Based Proteomic Analysis Reveals Potential Serum Biomarkers for Pediatric Non-Hodgkin's Lymphoma.

Authors:  Runhong Yu; Linna Cheng; Shiwei Yang; Yufeng Liu; Zunmin Zhu
Journal:  Front Oncol       Date:  2022-03-17       Impact factor: 6.244

Review 4.  Quantitative proteomics characterization of cancer biomarkers and treatment.

Authors:  Xiao-Li Yang; Yi Shi; Dan-Dan Zhang; Rui Xin; Jing Deng; Ting-Miao Wu; Hui-Min Wang; Pei-Yao Wang; Ji-Bin Liu; Wen Li; Yu-Shui Ma; Da Fu
Journal:  Mol Ther Oncolytics       Date:  2021-04-20       Impact factor: 7.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.